Alliance A021501 is a phase 2 randomized clinical trial that compares the efficacy of neoadjuvant modified FOLFIRINOX with or without hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas.1 The trial was led by the Alliance for Clinical Trials in Oncology with